Predictive Impact of C-reactive Protein to Albumin Ratio for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Receiving Nivolumab

Overview

Journal Sci Rep

Specialty Science

Date 2021 Feb 3

PMID 33531609

Citations 20

Authors

Kenro Tanoue

Shingo Tamura

Hitoshi Kusaba

Yudai Shinohara

Mamoru Ito

Kenji Tsuchihashi

Tsuyoshi Shirakawa

Taiga Otsuka

Hirofumi Ohmura

Taichi Isobe

Hiroshi Ariyama

Sakuya Koreishi

Yuzo Matsushita

Hozumi Shimokawa

Risa Tanaka

Kenji Mitsugi

Koichi Akashi

Eishi Baba

Affiliations

Soon will be listed here.

Abstract

Although the neutrophil to lymphocyte ratio (NLR) was reported to be a predictive biomarker for clinical outcomes in various types of cancer, including recurrent or metastatic head and neck cancer (R/M HNSCC) treated with nivolumab, the usefulness of the pretreatment C-reactive protein/albumin ratio (CAR) as a prognostic marker remains to be clarified. This study aimed to analyze the clinical usability of the CAR in comparison with that of the NLR. 46 R/M HNSCC patients treated with nivolumab were retrospectively analyzed. The optimal cutoff value for the CAR was calculated using receiver operating characteristic curve analysis. The optimal cutoff value for the CAR was set to 0.30. On multivariate analyses, a high CAR was significantly associated with poor overall survival (adjusted HR, 2.19; 95% CI, 1.42-3.47; p < 0.01) and progression-free survival (adjusted HR, 1.98; 95% CI, 1.38-2.80; p < 0.01). The overall response rate and disease control rate for the high CAR patients were lower than for the low CAR patients. The CAR had significantly higher area under the curve values than the NLR at 2 and 4 months. The pretreatment CAR might be an independent marker for prognosis and efficacy in R/M HNSCC patients treated with nivolumab.

Citing Articles

Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.

Kodama H, Kadowaki S, Ishizuka Y, Wakabayashi M, Sakakida T, Honda K Int J Clin Oncol. 2025; 30(3):480-488.

PMID: 39806030 DOI: 10.1007/s10147-025-02698-1.

Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis.

Su J, Li Y, Tan S, Cheng T, Luo Y, Zhang L Sci Rep. 2025; 15(1):446.

PMID: 39747391 PMC: 11695637. DOI: 10.1038/s41598-024-84890-3.

Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab.

Kasahara Y, Saijo K, Ueta R, Numakura R, Sasaki K, Yoshida Y Sci Rep. 2024; 14(1):28255.

PMID: 39548176 PMC: 11568322. DOI: 10.1038/s41598-024-79130-7.

Prognostic role of systemic inflammation response index in patients with non-small cell lung cancer: a meta-analysis.

Ye X, Dai M, Xiang Z BMJ Open. 2024; 14(11):e087841.

PMID: 39532372 PMC: 11575272. DOI: 10.1136/bmjopen-2024-087841.

Combined influence of physical activity and C-reactive protein to albumin ratio on mortality among older cancer survivors in the United States: a prospective cohort study.

An X, Li J, Li Y, Liu H, Bai J, Guo Q Eur Rev Aging Phys Act. 2024; 21(1):26.

PMID: 39358685 PMC: 11448037. DOI: 10.1186/s11556-024-00361-8.

References

Zandberg D, Strome S . The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014; 50(7):627-32. DOI: 10.1016/j.oraloncology.2014.04.003. View

Bilen M, Dutcher G, Liu Y, Ravindranathan D, Kissick H, Carthon B . Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer. 2018; 16(3):e563-e575. PMC: 5970007. DOI: 10.1016/j.clgc.2017.12.015. View

Ferris R . Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol. 2015; 33(29):3293-304. PMC: 4586169. DOI: 10.1200/JCO.2015.61.1509. View

Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R . Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer. 2002; 86(9):1396-400. PMC: 2375361. DOI: 10.1038/sj.bjc.6600257. View

Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27. DOI: 10.1056/NEJMoa0802656. View

Ravishankaran P, Karunanithi R . Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol. 2011; 9:18. PMC: 3045973. DOI: 10.1186/1477-7819-9-18. View

Zhou T, Zhan J, Hong S, Hu Z, Fang W, Qin T . Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer. Sci Rep. 2015; 5:10481. PMC: 4471724. DOI: 10.1038/srep10481. View

Yasumatsu R, Wakasaki T, Hashimoto K, Nakashima K, Manako T, Taura M . Monitoring the neutrophil-to-lymphocyte ratio may be useful for predicting the anticancer effect of nivolumab in recurrent or metastatic head and neck cancer. Head Neck. 2019; 41(8):2610-2618. DOI: 10.1002/hed.25737. View

Duffy S, Taylor J, Terrell J, Islam M, Li Y, Fowler K . Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008; 113(4):750-7. DOI: 10.1002/cncr.23615. View

10.

Baracos V, Martin L, Korc M, Guttridge D, Fearon K . Cancer-associated cachexia. Nat Rev Dis Primers. 2018; 4:17105. DOI: 10.1038/nrdp.2017.105. View

11.

Chung Y, Chang Y . Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol. 2003; 83(4):222-6. DOI: 10.1002/jso.10269. View

12.

Yu S, Zhou Z, Cai Q, Liang F, Han P, Chen R . Prognostic value of the C-reactive protein/albumin ratio in patients with laryngeal squamous cell carcinoma. Onco Targets Ther. 2017; 10:879-884. PMC: 5317306. DOI: 10.2147/OTT.S128391. View

13.

Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K . Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer. Ann Surg Oncol. 2015; 23(3):900-7. DOI: 10.1245/s10434-015-4948-7. View

14.

Ohmura H, Yamaguchi K, Hanamura F, Ito M, Makiyama A, Uchino K . OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody. Br J Cancer. 2020; 122(10):1507-1517. PMC: 7217874. DOI: 10.1038/s41416-020-0810-1. View

15.

Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T . Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab. Clin Lung Cancer. 2017; 19(2):e171-e176. DOI: 10.1016/j.cllc.2017.09.002. View

16.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

17.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

18.

Liu Z, Shi H, Chen L . Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis. BMC Cancer. 2019; 19(1):1161. PMC: 6884775. DOI: 10.1186/s12885-019-6373-y. View

19.

Kuboki A, Kanaya H, Nakayama T, Konno W, Goto K, Nakajima I . Prognostic value of C-reactive protein/albumin ratio for patients with hypopharyngeal and laryngeal cancer undergoing invasive surgery involving laryngectomy. Head Neck. 2018; 41(5):1342-1350. DOI: 10.1002/hed.25565. View

20.

Haruki K, Shiba H, Shirai Y, Horiuchi T, Iwase R, Fujiwara Y . The C-reactive Protein to Albumin Ratio Predicts Long-Term Outcomes in Patients with Pancreatic Cancer After Pancreatic Resection. World J Surg. 2016; 40(9):2254-60. DOI: 10.1007/s00268-016-3491-4. View